By Josh White
Date: Monday 07 Apr 2025
(Sharecast News) - Verici Dx has reported its highest-ever quarterly order rate for its Tutivia transplant diagnostic test in an update on Monday, with 292 orders in the first quarter of 2025, representing a 68% increase over the prior quarter, although it revised down its revenue forecasts amid some market delays.
By Josh White
Date: Friday 11 Oct 2024
(Sharecast News) - Verici Dx, a developer of advanced clinical diagnostics for organ transplants, announced an extension to its timeline for submitting supplemental information to the US Centers for Medicare and Medicaid Services in support of coverage determination for its 'Tutivia' test.
By Josh White
Date: Monday 01 Jul 2024
(Sharecast News) - Verici Dx, a developer of advanced clinical diagnostics for organ transplants, announced a significant milestone achievement under its agreement with Thermo Fisher Scientific on Monday.
Currency | UK Pounds |
Share Price | 1.25p |
Change Today | 0.000p |
% Change | 0.00 % |
52 Week High | 8.00 |
52 Week Low | 1.13 |
Volume | 114,203 |
Shares Issued | 242.54m |
Market Cap | £3.03m |
Beta | 0.04 |
RiskGrade | 429 |
Value |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Price Trend |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Income | ![]() |
---|
Growth | ![]() |
---|
No dividends found |
You are here: research